First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials
Title:
First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials
Author:
Schuler, M. Paz-Ares, L. Sequist, L.V. Tan, E.H. Mok, T. Hirsh, V. O’Byrne, K. Zhang, L. Yamamoto, N. Boyer, M. Shah, R. Bennouna, J. Dickgreber, N.J. De Grève, J. Love, J. Märten, A. Fan, J. Ehrnrooth, E. Park, K. Yang, J.C.H.